Search

everythinglearnresearchcommunity

for

Search:↓

The new chemotherapy combination for advanced lung cancer showed a 35.7% response rate but caused significant side effects.

Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.

The combination treatment showed a higher response rate but no significant survival benefits.

Bexxar is highly effective as a first treatment for non-Hodgkin's lymphoma, with most patients alive and many in remission after eight years.

Mitoxantrone is effective for treating acute leukemia, especially in older patients, with a lower risk of heart damage.

A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.

Trastuzumab deruxtecan is effective for HER2-positive breast cancer but requires careful management of side effects.

Effective management of side effects is crucial for safe use of sacituzumab govitecan in advanced breast cancer treatment.

A new treatment using nanoparticles can effectively prevent and reduce hair loss caused by chemotherapy.

Anti-CD19 therapy may help treat SLE and NMOSD.

Tofacitinib helped a woman regrow hair with no major side effects.

A patient developed nerve problems as a side effect of a hair loss treatment called tofacitinib.

Certain immune markers may predict chemotherapy response in mesothelioma, and nivolumab is a tolerable and effective treatment for advanced non-small cell lung cancer.

Tofacitinib and low-dose IL-2 may help maintain hair regrowth in alopecia areata without ongoing treatment.

Mitoxantrone with a corticosteroid helps manage symptoms for some advanced prostate cancer patients but doesn't extend life.

MK-5108 is safe and shows potential against tumors, especially alone.

Tofacitinib citrate improved nail dystrophy and pain in patients with alopecia universalis without causing side effects.

Pemigatinib may be effective for treating ZMYM2::FGFR1 fusion-positive leukemia.

ZSYY001 is safe, well-tolerated, and shows promise for treating advanced solid tumors.

Tofacitinib taken by mouth helps treat hair loss in children.

The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.

Tofacitinib successfully treated a woman's severe symptoms from a rare autoimmune condition.

Bortezomib chemotherapy can cause temporary skin rashes.

Tofacitinib is a promising treatment for children with rheumatic diseases.

A cancer patient's hair became permanently curly after treatment with nivolumab.

The drug TGU was ineffective against small cell lung cancer and caused significant bone marrow suppression.

Tofacitinib helps mice grow more hair by increasing noggin and BMP4 levels, possibly better than minoxidil.

The combination of mitoxantrone, etoposide, and prednisolone is effective for treating relapsed lymphoma with manageable side effects.

RC48 shows promise for treating certain advanced cancers, but more research is needed.

A medicine called tofacitinib worked to treat a hair loss condition linked with a muscle and skin disease.